Advanced Search

Technical Analysis for ALLO - Allogene Therapeutics, Inc.

Grade Last Price % Change Price Change
D 32.34 -0.52% -0.17
ALLO closed down 0.52 percent on Monday, April 19, 2021, on 52 percent of normal volume.
Earnings due: May 4
*** please verify all earnings dates ***
5 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Flat
Historical ALLO trend table...
Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.52%
Narrow Range Bar Range Contraction -0.52%
NR7 Range Contraction -0.52%
Inside Day Range Contraction -1.58%
Up 3 Days in a Row Strength -1.58%
Slingshot Bearish Bearish Swing Setup 0.59%
Stochastic Buy Signal Bullish 0.59%
Oversold Stochastic Weakness 0.59%
Lower Bollinger Band Walk Weakness 4.88%
Multiple of Ten Bullish Other 4.88%
Older End-of-Day Signals for ALLO ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 16 hours ago
Down 2 % about 16 hours ago
10 DMA Resistance about 18 hours ago
10 DMA Support about 18 hours ago
Down 1% about 18 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators Basic chart:

Profile

Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Life Sciences Stem Cells Cell Biology Cell Therapy Therapies For Cancer Adoptive Cell Transfer

Is ALLO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Apr 19 FDA clears Allogene Therapeutics' ALLO-605 application in multiple myeloma
Apr 19 Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR™ Candidate, for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Apr 12 Allogene and Springworks starts dosing in early-stage multiple myeloma study
Apr 12 Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma
Apr 10 Allogene Therapeutics Presents Preclinical Research Highlighting a Novel TurboCAR™ T Cell Technology Designed to Overcome Immune Suppression in Solid Tumors at the American Association for Cancer Research (AACR) Virtual 2021 Meeting
Apr 5 Allogene: World Leader In Allogeneic CAR-T
Mar 27 Allogene Therapeutics (ALLO) Up 3% Since Last Earnings Report: Can It Continue?
Mar 1 Allogene Therapeutics (ALLO) Investor Presentation - Slideshow
Feb 28 Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q4 2020 Results - Earnings Call Transcript
Feb 26 Allogene (ALLO) Q4 Earnings Top Estimates, Pipeline Advances
See more ALLO news...

Indicators

Indicator Value
52 Week High 55.0
52 Week Low 24.85
Average Volume 752,410
200-Day Moving Average 34.53
50-Day Moving Average 34.58
20-Day Moving Average 33.43
10-Day Moving Average 32.30
Average True Range 1.79
ADX 21.62
+DI 17.55
-DI 26.02
Chandelier Exit (Long, 3 ATRs ) 33.05
Chandelier Exit (Short, 3 ATRs ) 34.51
Upper Bollinger Band 36.82
Lower Bollinger Band 30.03
Percent B (%b) 0.34
BandWidth 20.34
MACD Line -0.84
MACD Signal Line -0.72
MACD Histogram -0.1178
Fundamentals Value
Market Cap 4.54 Billion
Num Shares 140 Million
EPS -2.07
Price-to-Earnings (P/E) Ratio -15.62
Price-to-Sales 0.00
Price-to-Book 4.05
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 33.74
Resistance 3 (R3) 33.67 33.14 33.50
Resistance 2 (R2) 33.14 32.78 33.17 33.42
Resistance 1 (R1) 32.74 32.57 32.94 32.81 33.35
Pivot Point 32.21 32.21 32.31 32.24 32.21
Support 1 (S1) 31.81 31.85 32.01 31.88 31.33
Support 2 (S2) 31.28 31.64 31.31 31.26
Support 3 (S3) 30.88 31.28 31.18
Support 4 (S4) 30.95